Abstract:Approximately 15–30% of human non-small cell lung cancers (NSCLC) carry K-ras mutations, among which point mutations at codon 12 are the most common. This study characterizes the anti-tumor effect of an anti-K-ras ribozyme adenoviral vector (KRbz-ADV; replication-deficient, E1-deleted Ad5 backbone) against NSCLC lines that express the relevant mutation (K-ras codon 12 GGT → GTT; H441 and H1725). KRbz-ADV significantly inhibited tumor cell growth (38–94% reduction by 3H-thymidine uptake) in a time- and dose-dependent manner, but produced minimal growth inhibition on normal epithelial cells, or NSCLC H1650 cells that lack the relevant mutation. The in vivo anti-tumorigenic effect of KRbz-ADV treatment was characterized with cell line xenografts in nu/nu mice. Pre-treatment with KRbz-ADV (10 or 20 p.f.u. per cell) completely abrogated subcutaneous engraftment of H441 (n = 13) or H1725 cells (n = 8), as compared with a 100% tumor take and progressive tumor growth in animals that received untreated tumor cells, or control vector (luciferase-adenovirus/Luc-ADV)-treated tumor cells. Pre-treatment with a mutant anti-K-ras ribozyme adenoviral vector (mutKRbz-ADV), which has the same specificity as KRbz but lacks ribozyme catalytic activity, did not produce an anti-tumorigenic effect. The in vivo effect of KRbz-ADV treatment was further examined by initiating injections (2 × 109 p.f.u.) at 7 days after tumor induction. Pre-existing tumor growth was reduced by 39% by a single intratumoral injection. Repeat injections (three or five KRbz-ADV-intratumoral injections at 2 × 109 p.f.u. every other day) resulted in complete tumor regression in five of seven mice. In contrast, single or multiple injections of control vector Luc-ADV did not significantly alter tumor xenograft outcome. Ribozyme expression was confirmed in H441 cells that demonstrated reduced growth after KRbz-ADV treatment. Reduced growth corresponded to significantly lowered levels of K-ras mRNA, as defined by RT-PCR (51% of untreated level, n = 3) and RNase protection assay (56% of untreated level, n = 4) analyses. Further, 37.5% of KRbz-ADV-treated cells underwent apoptosis, as compared with 11.7%, and 19.0% in untreated and Luc-ADV-treated cultures, respectively. A significantly higher proportion of KRbz-ADV-treated H441 cells (58.2%) underwent apoptosis when maintained under anchor-independent conditions that simulate in vivo tumorigenesis (‘anoikis’). This is the first report that demonstrates that KRbz-ADV can effectively inhibit in vivo tumorigenesis, and produces regression of pre-existing human lung tumor xenografts having the relevant K-ras mutation.

Construction of an Adenovirus Vector Encoding Mutant K-ras siRNA and Its Effect on the H441 Human Lung Cancer Cell Line

Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells.

[Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo]

Generation of Ribozyme-Adenoviral Vector Against K-ras Mutant Human Lung Cancer Cells

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Construction of recombinant lentivirus vector containing retinoic acid-induced gene G and its effect on human lung cancer A549 cell line

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Construction of recombinant adenovirus vector encoding VEGF siRNA and its inhibitory effect on K562 cell proliferation

Construction of the Recombinant Adenovirus RNA Interference Vector of Human Hypoxia-Inducible Transcription Factor-1Α Gene and Its Effect on Expression of HIF-1α Gene in Human Lung Adenocarcinoma Cells SPCA-1

Construction of the Adenovirus Expressing Mice EGFR SiRNA and its Effect on the Mice EL-4 Cell Line

Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice

Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering Rna

Construction of adenovirus vector expressing RANTES gene and its anti-cancer effect

Construction of recombinant adenoviruses containing small interfering RNA targeting rat protein tyrosine phosphatase 1B

[Construction of Recombinant Adenovirus Vector of Mouse Keratinocyte Growth Factor].

Construction of the recombinant adenovirus vector with eGFR antisense cDNA of controlling cell cycle

The Study of Specific Inhibition of Mutant K-ras Gene Expression by Short Interfering RNAs in Human Pancreatic Carcinoma Cell PANC-1

A method of delivering an anti-p21Ras single-chain antibody fragment to tumor sites in vivo

Construction of recombinant adenovirus vector of Livin siRNA and its effects on proliferation,apoptosis and drug resistance of K562 cells

[Construction of Recombinant Adenovirus Vector Carrying Cell Cycle Controlling Gene-P14arf].

Construction and Packaging of Pseudotype Retrovirus Containing Human N-ras Cdna Antisense Sequence and Its Biological Effects on Human Hepatoma Cells